Dbh, CPTAC-3459 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

non-CPTAC-3459: View additional VVTVLAR data

10 20 30 40 50
MQAHLSHQPC WSSLPSPSVR EAASMYGTAV AIFLVILVAA LRGSEPPESP
60 70 80 90 100
FPYHIPLDPE GILELSWNVS YVQEIIHFQL QVQGLRAGVL FGMSDRGEME
110 120 130 140 150
NADLIMLWTD GDRAYFADAW SDRKGQIHLD SQQDYQLLQA QRTRDGLSLL
160 170 180 190 200
FKRPFVTCDP KDYVIEDDTV HLVYGILEEP FQSLEAINTS GLHTGLQRVQ
210 220 230 240 250
LLKSEVPTPS MPEDVQTMDI RAPDILIPDN ETTYWCYITE LPPRFPRHHI
260 270 280 290 300
IMYEAIVTEG NEALVHHMEV FQCAAESEDF PQFNGPCDSK MKPDRLNYCR
310 320 330 340 350
HVLAAWALGA KAFYYPKEAG VPFGGPGSSP FLRLEVHYHN PRKIQGRQDS
360 370 380 390 400
SGIRLHYTAT LRRYDAGIME LGLVYTPLMA IPPQETAFVL TGYCTDKCTQ
410 420 430 440 450
MALQDSGIHI FASQLHTHLT GRKVVTVLAR DGQERKVVNR DNHYSPHFQE
460 470 480 490 500
IRMLKKVVTV YPGDVLITSC TYNTENKTLA TVGGFGILEE MCVNYVHYYP
510 520 530 540 550
QTELELCKSA VDDGFLQKYF HMVNRFSSEE VCTCPQASVP QQFSSVPWNS
560 570 580 590 600
FNRDMLKALY DYAPISMHCN KTSAVRFPGE WNLQPLPKIT STLEEPTPRC
610 620 622
PIRQTQSPAN PTVPITTEAD AE

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for non-CPTAC-3459 Collapse assay details

Data source: Panorama

Official Gene Symbol

Dbh

Peptide Sequence

VVTVLAR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

424

Peptide End

430

CPTAC ID

non-CPTAC-3459

Peptide Molecular Mass

756.4858

Species

Mus musculus (Mouse)

Assay Type

Direct MRM

Matrix

Plasma

Submitting Laboratory

UVic-Genome BC Proteomics Centre

Submitting Lab PI

Christoph Borchers


Publication

View Details (opens in a new window)

Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. Michaud SA, Sinclair NJ, Petrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y Eshghi A1, Richard VR, Sickmann A, Borchers CH. Commun Biol. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

Agilent 6490/6495 QQQ

Internal Standard

synthetic peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

1290 LC (Agilent)

Column Packing

Zorbax Eclipse Plus C18, 1.8 µm

Column Dimensions

2.1 x 150 mm

Flow Rate

400 µL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y6 (1+) | 17 | 5.4 | 4 | 16.4 | 6.5 | 4.5 | 23.6 | 8.5 | 6 | 15 | 15 | 15 | | y5 (1+) | 4.4 | 3.5 | 4.1 | 6.7 | 5.4 | 4 | 8 | 6.4 | 5.7 | 15 | 15 | 15 | | y4 (1+) | 19.5 | 6.8 | 3 | 19.6 | 7.6 | 6.3 | 27.6 | 10.2 | 7 | 15 | 15 | 15 | | y3 (1+) | 37.5 | 4.8 | 2.3 | 55.5 | 11.4 | 3.7 | 67 | 12.4 | 4.4 | 15 | 15 | 15 | | b4 (2+) | 40.9 | 17.1 | 14.1 | 49.2 | 20.9 | 11.3 | 64 | 27 | 18.1 | 15 | 15 | 15 | | sum | 9.7 | 2.9 | 3.4 | 11.4 | 5.1 | 3.6 | 15 | 5.9 | 5 | 15 | 15 | 15 |



Additional Resources and Comments